FIELD: chemistry.
SUBSTANCE: invention relates to chemistry of organic compounds, pharmacology and medicine, and concerns new peptides characterized by anticancer activity, which can be used in particular for prevention and treatment of tumour diseases in a subject. In addition, the present invention also includes use of the peptides according to the invention for treating tumour diseases, as well as pharmaceutical compositions for treating tumour diseases, which include the peptides according to the invention.
EFFECT: peptides with anticancer activity are disclosed.
9 cl, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
COMBINATION OF DEHYDROXYMETHYL EPOXYQUINOMYCIN (DHMEQ) AND CYTOSTATICS FOR TREATING OVARIAN CANCER | 2018 |
|
RU2704020C1 |
COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
MYBL2 EPITOPE PEPTIDES AND VACCINES CONTAINING THEM | 2009 |
|
RU2496787C2 |
METHOD OF TREATING CANCER (VERSIONS) | 2006 |
|
RU2447889C2 |
EPITOPIC PEPTIDES RAB6KIFL/KIF20A AND VACCINES CONTAINING THEM | 2009 |
|
RU2532105C2 |
CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
17ALPHA-BENZOATE OF CORTEXOLONE FOR USE IN TREATING TUMOURS | 2015 |
|
RU2712752C2 |
MODIFIED MELK PEPTIDES AND VACCINES CONTAINING LATTER | 2011 |
|
RU2580035C2 |
PHARMACEUTICAL, CONTAINING EPITOPE PEPTIDES HIG2 AND URLC10, FOR CANCER TREATMENT, METHODS AND MEANS FOR INDUCTION OF ANTIGEN-PRESENTING CELL AND CYTOTOXIC T-LYMPHOCYTE (CTL), ANTIGEN-PRESENTING CELL AND CTL, OBTAINED THEREOF, METHOD AND MEANS OF IMMUNE ANTI-CANCER RESPONSE | 2009 |
|
RU2529373C2 |
COMBINATIONS | 2015 |
|
RU2715236C2 |
Authors
Dates
2025-05-19—Published
2024-04-05—Filed